For 2011 and 2012, the data only represent antimicrobial VMPs imported by wholesalers; from 2013, the data represent all sales from wholesalers to end-users (veterinarians, pharmacies, producers of medicated feed and farmers) of VMPs obtained by import and from national manufacturers.

* The class ‘Others’ includes sales of the following sub-classes: Imidazole derivatives (metronidazole), and Other antibacterials (novobiocin, rifaximin and spectinomycin). Of note is that some of the sales could be for non-food-producing animals.
Datasets for 2011 and 2012 only included data for antimicrobial VMPs imported by wholesalers; sales of antimicrobial VMPs to end-users by national manufacturers were therefore not accounted for. Since 2013, antimicrobial VMPs produced by national manufacturers have also been dispensed by wholesalers. For the years 2013 to 2020, the data include sales from wholesalers to other wholesalers and to end-users (pharmacies, military forces, the State Veterinary and Food Administration, veterinarians, farmers and feed mills), covering both import data and antimicrobial VMPs produced by national manufacturers. This difference in coverage is thought to be the main reason for differences in sales between the periods 2011–2012 and 2013–2020. Data for the period 2011–2012 are not comparable with data for 2013–2020. Although overall sales fluctuated during 2013–2020, sales in 2020 were 12.4% lower than in 2013. Slovak manufacturers of VMPs, including premixes, mainly produce products with tetracyclines, penicillins, sulfonamides and pleuromutilins — which were the highest-selling classes in 2020 — and with fluoroquinolones.

Sales (mg/PCU) of 3rd- and 4th-generation cephalosporins in Slovakia fluctuated between 2013 and 2020. In 2013, this subclass accounted for 0.67% (0.40 mg/PCU) of total sales; in 2020, the figure was 0.96% (0.50 mg/PCU) and aggregated sales for the 25 countries were 0.16 mg/PCU.

Sales (mg/PCU) of fluoroquinolones also fluctuated between 2013 and 2020. In 2013 and 2020, the proportions of total sales for this subclass were 4.75% (2.81 mg/PCU) and 6.61% (3.43 mg/PCU), respectively. In 2020, aggregated sales for the 25 countries were 2.21 mg/PCU.

Sales (mg/PCU) of other quinolones decreased by 82.6% from 2013 to 2020; in 2013, this subclass accounted for 0.21% (0.12 mg/PCU) of total sales, while in 2020 this figure was 0.04% (0.021 mg/PCU). In 2020, aggregated sales for the 25 countries were 0.16 mg/PCU.

Sales (mg/PCU) of polymyxins fluctuated between 2013 and 2020. In 2013, this subclass accounted for 1.93% (1.15 mg/PCU) of the total sales; in 2020, the figure was 3.86% (2.0 mg/PCU) and aggregated sales for the 25 countries were 2.58 mg/PCU.